Peel Hunt reaffirmed their buy rating on shares of Craneware plc (LON:CRW) in a research report sent to investors on Monday. Peel Hunt currently has a GBX 1,495 ($19.83) price target on the stock.
Separately, N+1 Singer restated a hold rating on shares of Craneware plc in a report on Tuesday, September 5th.
Craneware plc (LON:CRW) opened at 1292.50 on Monday. Craneware plc has a 12 month low of GBX 950.00 and a 12 month high of GBX 1,885.00. The company has a 50-day moving average of GBX 1,307.03 and a 200-day moving average of GBX 1,267.87. The stock’s market cap is GBX 348.47 million.
ILLEGAL ACTIVITY WARNING: “Peel Hunt Reaffirms “Buy” Rating for Craneware plc (CRW)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/05/peel-hunt-reaffirms-buy-rating-for-craneware-plc-crw.html.
The business also recently declared a dividend, which will be paid on Thursday, December 7th. Investors of record on Thursday, November 9th will be paid a GBX 11.30 ($0.15) dividend. This represents a yield of 0.85%. The ex-dividend date is Thursday, November 9th. This is an increase from Craneware plc’s previous dividend of $8.70.
About Craneware plc
Craneware plc is a United Kingdom-based company, which is engaged in the development, licensing and ongoing support of computer software for the United States healthcare industry. The Company’s Value Cycle Solutions span over five product families, which include Patient Engagement, Charge Capture & Pricing, Coding Integrity, Cost Analytics, and Revenue Collection & Retention.
Receive News & Ratings for Craneware plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Craneware plc and related companies with MarketBeat.com's FREE daily email newsletter.